China Innovative Drugs on the Global Stage – Insights from BIO-Europe 2026
China is becoming a new focal point for global pharmaceutical partnerships. How is the European pharmaceutical industry discussing Chinese innovative drugs at BIO-Europe?
The 32nd BIO-Europe conference was held in Cologne, Germany, from November 9 to 11, 2026. Across several industry discussions focused on China biotech, key topics included ADC technology platforms, clinical data reliability, cross-border License-out partnerships and CMC. [1]
These discussions show that China innovative drugs on the global stage are increasingly evaluated by international pharmaceutical companies for technology platforms, clinical evidence, and global supply capabilities, beyond development efficiency alone.
China Innovative Drugs Are Becoming an Important Source of Global R&D Pipelines
In recent years, China innovative drug development has remained highly active across multiple therapeutic areas, including oncology and autoimmune diseases. Technology approaches have also expanded beyond traditional small molecules to include ADCs, bispecific antibodies, and cell therapies.
The internationalization of Chinese innovative drugs is becoming increasingly evident.
Drugs such as zanubrutinib, toripalimab, and fruquintinib have received FDA approval and represent important milestones in the global expansion of Chinese innovative medicines.[2-4]
Meanwhile, Chinese pharmaceutical companies are introducing more R&D programs into multinational pharmaceutical companies’ global development systems through License-out partnerships.
As China innovative drugs on the global stage enter international markets, clinical differentiation, the long-term development potential of technology platforms, clinical data reliability, manufacturing quality, and supply chain systems have all become important factors in evaluating partnership opportunities.
These considerations have also become significant topics in discussions at BIO-Europe this year.
ADCs: International Attention Is Expanding from Individual Drugs to Technology Platforms
ADCs were among the important technology areas discussed at BIO-Europe 2026, and China biotech has become an increasingly relevant part of the conversation.
Chinese companies continue to advance ADC development, strengthening China innovative drugs on the global stage through capabilities spanning antibodies, linkers, payloads, and conjugation processes.
International partnerships involving programs such as disitamab vedotin have also increased global attention on China’s ADC development capabilities.[5]
As partnerships deepen, international partners are increasingly evaluating the completeness and long-term development potential of ADC technology platforms. Key considerations include: 🔽
- Antibody and target selection: Whether the company has appropriate target strategies and robust antibody screening capabilities.
- Linkers and payloads: Whether linker stability, payload activity, and release mechanisms have been adequately validated.
- Conjugation processes: Whether the drug-to-antibody ratio (DAR) and product homogeneity are effectively controlled.
- Platform scalability: Whether the technology can be applied to different drug candidates and support continued optimization.
Clinical differentiation and the ability to achieve stable manufacturing scale-up also influence the long-term value of ADC programs.
Clinical Data: From Development Speed to International Recognition
China has substantial patient resources and extensive clinical trial experience. Clinical development efficiency has long been an important advantage attracting international attention to Chinese innovative drugs.
As cross-border partnerships deepen, international partners are asking more specific questions about clinical evidence: Can clinical data generated in China support development in different regions and regulatory review in overseas markets?
International partners typically focus on the following areas: 🔽
- Patient representativeness: Do participant characteristics reflect patient populations in target overseas markets?
- Trial design: Are endpoints, control regimens, and eligibility criteria aligned with international clinical development requirements?
- Safety data: Are adverse event records, reporting, and long-term follow-up complete?
- Data quality: Are source data, clinical documentation, and statistical analyses accurate, complete, and traceable?
- Further development: Are multi-regional clinical trials (MRCTs) or additional studies required?
These requirements affect the acceptability of clinical data across regulatory systems and influence the timelines and costs of subsequent development.
For Chinese biotech companies, international clinical development requires early coordination of patient populations, trial design, data management, and regulatory strategies.
Establishing clinical evidence that meets international standards, is verifiable, and provides sufficient scientific support will help strengthen China biotech global competitiveness.
License-out: From Single-Asset Licensing to Diverse Partnerships
License-out has long been an important pathway for the internationalization of Chinese innovative drugs. In recent years, collaboration models have gradually expanded from single-asset licensing to multi-asset partnerships, technology platform licensing, and joint development.
For example, ivonescimab, developed by Akeso, is being advanced internationally through its partnership with Summit Therapeutics in the United States.[6] Disitamab vedotin, developed by RemeGen, has also entered international collaboration through licensing arrangements.
These partnerships highlight how China innovative drugs on the global stage are advancing through independently developed assets and international drug development collaborations.
Meanwhile, international collaboration models have become increasingly diverse: 🔽
- Single-asset licensing: Granting overseas pharmaceutical companies development and commercialization rights for a drug in specific territories.
- Multi-asset partnerships: Including multiple drug candidates in long-term collaboration arrangements.
- Technology platform partnerships: Collaborating around R&D platforms such as ADCs and bispecific antibodies.
- Joint development: Sharing clinical development costs and responsibilities between partners.
- NewCo models: Establishing new companies to integrate R&D assets, funding, and international resources.
This evolution indicates that relationships between international pharmaceutical companies and Chinese biotech firms are gradually moving beyond asset acquisition toward long-term R&D collaboration.
CMC and Supply Chains: Globalization Must Extend Beyond Clinical Development and Licensing
BIO-Europe 2026 also highlighted China biomanufacturing as an important topic, including CDMO development, international regulatory requirements, manufacturing partnerships, and supply chain risks.
For ADCs and biologics, manufacturing involves complex process controls. Antibody quality, conjugation processes, impurity control, and batch consistency can all affect final product quality.
If clinical manufacturing processes cannot be reliably scaled up, subsequent development and regulatory timelines may be affected.
International partners typically evaluate manufacturing site quality management systems, process scale-up capabilities, critical raw material supplies, technology transfer, and cross-border transportation and temperature control.
CMC should advance alongside drug discovery and clinical development, supported by stable, compliant, and traceable manufacturing and supply systems essential for global commercialization.
The Next Stage of Global Competitiveness for Chinese Innovative Drugs
The discussions at BIO-Europe 2026 suggest that international markets are evaluating Chinese innovative drugs through an increasingly comprehensive framework.
The future competitiveness of China innovative drugs on the global stage will depend primarily on four dimensions:
| Competitive Dimension | Key International Considerations |
|---|---|
| Innovative R&D | Differentiated targets, mechanisms, and clinical value |
| Clinical development | Reliable data supporting development in overseas markets |
| International partnerships | Clear rights allocation and global collaboration strategies |
| Manufacturing and supply chains | Stable, compliant, and reliable production and cross-border supply |
The global expansion of Chinese innovative drugs is evolving beyond licensing deals into broader competition across R&D, clinical development, manufacturing, and supply chains.
For Chinese pharmaceutical companies, sustained development of clinically meaningful products and the ability to meet international standards in drug development and supply are key to establishing a lasting presence in global markets.
DengYueMed: Connecting China’s Pharmaceutical Supply Chains with International Markets
The internationalization of China’s pharmaceutical industry involves not only innovative drug R&D, technology licensing, and joint development, but also pharmaceutical procurement, import and export coordination, quality management, and cross-border supply chain services.
Headquartered in Hong Kong, DengYueMed is a China pharmaceutical wholesaler and exporter connecting Chinese pharmaceutical resources with global markets through procurement, import and export, customs clearance, quality inspection, and logistics services.
As China innovative drugs on the global stage continue to gain attention, stable, compliant, and traceable supply chains remain an important foundation for international partnerships.
Explore China Pharmaceutical Export Solutions
FAQ about China Innovative Drugs on the Global Stage
Why are China innovative drugs gaining global attention?
China innovative drugs are gaining global attention through differentiated drug candidates, advanced technology platforms, clinical development capabilities, and expanding international licensing partnerships.
Which Chinese innovative drugs have received FDA approval?
Examples include zanubrutinib, toripalimab, and fruquintinib, which have received FDA approval for specific indications, demonstrating the growing international presence of Chinese-developed medicines.
What makes China’s ADC technology attractive to international pharmaceutical companies?
China’s ADC capabilities span antibody discovery, linker and payload development, conjugation technologies, and platform scalability, creating opportunities for differentiated drug development and international partnerships.
What is License-out in China’s pharmaceutical industry?
License-out allows Chinese pharmaceutical companies to grant overseas partners development and commercialization rights for drug candidates or technology platforms, often supporting global clinical development and commercialization.
Why are CMC and supply chains important for China innovative drugs entering global markets?
Reliable CMC capabilities and stable, compliant, and traceable supply chains support manufacturing consistency, regulatory compliance, technology transfer, and international pharmaceutical partnerships.
References
- BIO-Europe 2026 – Official Event Guide. Informa Connect.
https://eventguides.informaengage.com/event-guides-26/bio-europe-2026/ - FDA – FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia. U.S. Food and Drug Administration, August 31, 2021.
https://www.fda.gov/drugs/cancer-approvals/fda-approves-zanubrutinib-waldenstroms-macroglobulinemia - FDA – FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma. U.S. Food and Drug Administration, October 27, 2023.
https://www.fda.gov/drugs/cancer-approvals/fda-approves-toripalimab-tpzi-nasopharyngeal-carcinoma - FDA – FDA Approves Fruquintinib in Refractory Metastatic Colorectal Cancer. U.S. Food and Drug Administration, November 8, 2023.
https://www.fda.gov/drugs/cancer-approvals/fda-approves-fruquintinib-refractory-metastatic-colorectal-cancerFDA – FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor. U.S. Food and Drug Administration, November 10, 2026.
https://www.fda.gov/drugs/cancer-approvals/fda-approves-pimicotinib-symptomatic-tenosynovial-giant-cell-tumor - Seagen Inc. – Form 8-K: License Agreement with RemeGen for Disitamab Vedotin (RC48). U.S. Securities and Exchange Commission, September 21, 2021.
https://www.sec.gov/Archives/edgar/data/1060736/000119312521278354/d196037d8k.htm - Summit Therapeutics – 2026 Second Quarter Form 10-Q: Akeso License and Collaboration Agreement. U.S. Securities and Exchange Commission, 2026.
https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/smmt-20260630.htm
